Parkman Healthcare Partners LLC Invests $7.70 Million in Boston Scientific Corporation $BSX

Parkman Healthcare Partners LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 180,481 shares of the medical equipment provider’s stock, valued at approximately $7,703,000.

Several other large investors also recently added to or reduced their stakes in the business. Kelleher Financial Advisors purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at about $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific in the first quarter worth approximately $28,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on BSX. Raymond James Financial reiterated an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a research report on Wednesday, July 29th. Finally, BTIG Research reduced their target price on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 2.8%

Shares of BSX opened at $48.98 on Tuesday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a 50 day simple moving average of $46.38 and a two-hundred day simple moving average of $57.32. The firm has a market cap of $70.99 billion, a P/E ratio of 19.83, a P/E/G ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue was up 7.5% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.